Literature DB >> 23542232

Cell-based therapies for ocular inflammation.

John V Forrester1, Raymond J Steptoe, Izabela P Klaska, Cristina Martin-Granados, Harminder S Dua, Mariapia A Degli-Esposti, Matthew E Wikstrom.   

Abstract

Since the plasticity and the potential for re-programming cells has become widely accepted, there has been great interest in cell-based therapies. These are being applied to a range of diseases, not least ocular diseases, where it is assumed that there is a reduced risk of immune rejection although this may be more perceived than real. There are two broad classes of cell-based therapies: those aimed at restoring structure and function of specific tissues and cells; and those directed towards restoring immunological homeostasis by controlling the damaging effects of inflammatory disease. Stem cells of all types represent the first group and prototypically have been used with the aim of regenerating failing cells. In contrast, immune cells have been suggested as potential modulators of inflammation. However, there is functional overlap in these two applications, with some types of stem cells, such as mesenchymal stem cells, demonstrating a potent immunomodulatory effect. This review summarises recent information on cell based therapies for ocular disease, with special emphasis on ocular inflammatory disease, and explores current uses, potential and limitations.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23542232     DOI: 10.1016/j.preteyeres.2013.02.002

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  7 in total

Review 1.  High-risk corneal allografts: A therapeutic challenge.

Authors:  Tian Yu; Vijayalakshmi Rajendran; May Griffith; John V Forrester; Lucia Kuffová
Journal:  World J Transplant       Date:  2016-03-24

2.  Cornea-Derived Mesenchymal Stromal Cells Therapeutically Modulate Macrophage Immunophenotype and Angiogenic Function.

Authors:  Medi Eslani; Ilham Putra; Xiang Shen; Judy Hamouie; Asha Tadepalli; Khandaker N Anwar; John A Kink; Samaneh Ghassemi; Gaurav Agnihotri; Sofiya Reshetylo; Alireza Mashaghi; Reza Dana; Peiman Hematti; Ali R Djalilian
Journal:  Stem Cells       Date:  2018-01-27       Impact factor: 6.277

3.  Lipopolysaccharide-primed heterotolerant dendritic cells suppress experimental autoimmune uveoretinitis by multiple mechanisms.

Authors:  Izabela P Klaska; Elizabeth Muckersie; Cristina Martin-Granados; Maria Christofi; John V Forrester
Journal:  Immunology       Date:  2016-12-18       Impact factor: 7.397

4.  A Synthesized Glucocorticoid- Induced Leucine Zipper Peptide Inhibits Retinal Müller Cell Gliosis.

Authors:  Ruiping Gu; Xinyi Ding; Wenyi Tang; Boya Lei; Chen Jiang; Gezhi Xu
Journal:  Front Pharmacol       Date:  2018-04-06       Impact factor: 5.810

5.  I-alowCD11bhigh DC Regulates the Immune Response in the Eyes of Experimental Autoimmune Uveitis.

Authors:  Yu Zhao; Jingwen Wang; Zhang Min; Li Peng; Shuhong Qi; Wei Lin
Journal:  Mediators Inflamm       Date:  2020-03-10       Impact factor: 4.711

Review 6.  Immune Privilege: The Microbiome and Uveitis.

Authors:  Christine Mölzer; Jarmila Heissigerova; Heather M Wilson; Lucia Kuffova; John V Forrester
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

7.  Corneal Mesenchymal Stromal Cells Are Directly Antiangiogenic via PEDF and sFLT-1.

Authors:  Medi Eslani; Ilham Putra; Xiang Shen; Judy Hamouie; Neda Afsharkhamseh; Soroush Besharat; Mark I Rosenblatt; Reza Dana; Peiman Hematti; Ali R Djalilian
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-10-01       Impact factor: 4.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.